logo
  Join        Login             Stock Quote

Is BioSante Pharmaceuticals Next In Line To Receive Institutional Praise?

 December 27, 2010 10:25 AM
 


The biotech universe has been a hot investment option towards the end of the year for those looking for high risk high reward equities. This industry offers investors a chance to find companies which price per share is valuated based on science rather than heavy influence from major indices and economic news around the world. Though often times it is hard to distinguish the golden eggs among the rotten ones, it is becoming increasingly popular to see investors and firms begin buying up companies prior to their upcoming FDA catalysts in anticipation of the news, often a few weeks or months in advance.

One of the companies looking to take advantage of the recent inflow of attention to the small cap biotechs is BioSante Pharmaceuticals, who has 2 upcoming catalysts for the first half of 2011 which could easily propel the company to new 52-week highs. It is expected in the coming weeks that they begin phase 2 study at Johns Hopkins cancer center for GVAX (therapeutic cancer vaccine) and also phase 3 results for their flagship product, LibiGel to support an NDA filing. With a market capitalization of only 112M, it isn't a surprise the company's Director, Ross Manango has been scooping up shares at $1.47 during December in anticipation of the company's forward looking events during the new year. The company has also increased cash on hand by nearly $6M from product revenues and partnerships year-over-year as its clinical pipeline continues to grow stronger, dispelling any worries of future dilution. (source:11/12/2010 10-Q EDGAR ONLINE)

[Related -Top Insider Purchases: ACAD, FCX, CLMS, EPZM, GHDX, SCMP]

[Related -Repros Therapeutics Inc (RPRX): This Insider Hits Home Runs]

Such occurences have recently been witnessed in XOMA whose shares rose a whopping 204.68% since last Monday's trading, Repros who jumped 82% on Thursday, and ACADIA who went on to gain 31% on Wednesday and Friday's market. Though no material news was formally announced neither XOMA nor ACADIA, the shares jumped solely in anticipation of upcoming FDA catalysts, with Repros being the exception of the three.  Repros reported positive developments for its experimental testosterone deficiency drug, Androxal.

What's most important to note is that all three of these companies saw heavy institutional accumulation during the last three months leading up to their anticipated catalysts, something BioSante has yet to experience.


Next Page >>12
iOnTheMarket Premium
Advertisement

Advertisement


Comments Closed


rss feed

Latest Stories

article imageWill The Real U.S. Market Please Reveal Itself?

Is it the small stock Russell 2000, in a pattern of rally attempts failing at lower highs since its March read on...

article imageTime To Chase Bill Gross?

Jason Zweig at the Wall Street Journal had a very good piece on whether to follow Bill Gross as he goes read on...

article imageA Bullish Sign For Uranium Could Send This Stock Soaring

On March 11, 2011, a massive 9.0-magnitude earthquake erupted about 45 miles east of the Japanese coast. read on...

article imageBanks' LCR-based Demand For Treasuries Moderates

One of the factors contributing to treasury market's strong performance this year has been the Liquidity read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.